Context Therapeutics (CNTX) Operating Leases (2022 - 2026)
Context Therapeutics (CNTX) posted Operating Leases of $122369.0 for Q1 2026, up 476.67% sequentially from $21220.0 in Q3 2025, and up 48.13% YoY from $82608.0 in Q1 2025.
Context Therapeutics (CNTX) Operating Leases (2022 - 2026) Analysis & Trends
Context Therapeutics has reported Operating Leases for 5 years, with the latest figure at $122369.0 in Q1 2026.
- Quarterly Operating Leases rose 48.13% year-over-year to $122369.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122369.0 (up 48.13% YoY) and the FY2024 annual result came in at $112064.0, changed N/A from the prior year.
- Operating Leases advanced to $122369.0 in Q1 2026 per CNTX's latest filing, from $21220.0 in the prior quarter.
- Over five years, Operating Leases peaked at $140200.0 in Q3 2024 and troughed at $7967.0 in Q2 2022.
- A 5-year average of $67616.5 and a median of $66500.0 in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 84.86% in 2025, then jumped 48.13% in 2026.
- Over 5 years, Operating Leases stood at $55000.0 in 2022, then sank by 85.51% to $7967.0 in 2023, then surged by 1306.6% to $112064.0 in 2024, then sank by 81.06% to $21220.0 in 2025, then soared by 476.67% to $122369.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $122369.0, $21220.0, and $52334.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 122,369.00 |
| Sep 30, 2025 | 21,220.00 |
| Jun 30, 2025 | 52,334.00 |
| Mar 31, 2025 | 82,608.00 |
| Dec 31, 2024 | 112,064.00 |
| Sep 30, 2024 | 140,200.00 |
| Jun 30, 2023 | 7,967.00 |
| Mar 31, 2023 | 31,669.00 |
| Dec 31, 2022 | 55,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 7,967.00 |
| Mar 31, 2022 | 100,000.00 |